EMA/93313/2021

European Medicines Agency decision

P/0119/2021

of 17 March 2021

on the acceptance of a modification of an agreed paediatric investigation plan for cobimetinib (Cotellic), (EMEA-001425-PIP01-13-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

European Medicines Agency decision

P/0119/2021

of 17 March 2021

on the acceptance of a modification of an agreed paediatric investigation plan for cobimetinib (Cotellic), (EMEA-001425-PIP01-13-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0025/2014 issued on 24 January 2014, the decision P/0124/2014 issued on 16 May 2014, the decision P/0065/2017 issued on 17 March 2017, the decision P/0216/2018 issued on 17 July 2018 and the decision P/0306/2019 issued on 10 September 2019,

Having regard to the application submitted by Roche Registration GmbH on 14 September 2020 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 29 January 2021, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for cobimetinib (Cotellic), film-coated tablet, age-appropriate oral formulation, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Roche Registration GmbH, Emil-Barell-Strasse 1, 79639 - Grenzach-Wyhlen, Germany.

EMA/PDCO/610739/2020
Amsterdam, 29 January 2021

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001425-PIP01-13-M05

Scope of the application

Active substance(s):

Cobimetinib

Invented name:

Cotellic

Condition(s):

Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue) with Ras, Raf or MEK pathway activation

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Film-coated tablet

Age-appropriate oral formulation

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Roche Registration GmbH

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Roche Registration GmbH submitted to the European Medicines Agency on 14 September 2020 an application for modification of

the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0025/2014 issued on 24 January 2014, the decision P/0124/2014 issued on 16 May 2014, the decision P/0065/2017 issued on 17 March 2017, the decision P/0216/2018 issued on 17 July 2018 and the decision P/0306/2019 issued on 10 September 2019.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 1 December 2020.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue) with Ras, Raf or MEK pathway activation

The waiver applies to:

- neonates and infants from birth to less than 6 months of age;
- film-coated tablet, age-appropriate formulation, oral use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition

Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue) with Ras, Raf or MEK pathway activation

2.1.1. Indication(s) targeted by the PIP

Treatment of children with a paediatric solid malignant tumour with known or expected Ras, Raf or MEK pathway activation, at first relapse or refractory to initial treatment

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 months to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Film-coated tablet

Age-appropriate oral formulation

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	**Study 1** Development of an age-appropriate oral formulation
Non-clinical studies	2	**Study 2** Toxicity and toxicokinetic study in juvenile rats **Study 3** In vitro and in vivo study on non-clinical model testing

Clinical studies	2	**Study 4** Multiple dose 2-stage trial to evaluate pharmacokinetics, safety and activity of cobimetinib in children from 6 months to less than 18 years of age with relapsed or refractory solid tumours with known or expected Ras, Raf or MEK pathway activation(GO29665/NCT02639546) **Study 5** deleted in procedure EMEA-001425-PIP01-13-M05
Extrapolation, Modelling and simulation studies	0	Not applicable
Other studies	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By July 2020
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue) with Ras, Raf or MEK pathway activation

Authorised indication(s):

- Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation

Authorised pharmaceutical form(s):

Film-coated tablet

Authorised route(s) of administration:

Oral use